Redhill Financial Statements From 2010 to 2024

RDHL Stock  USD 0.42  0.03  7.69%   
Redhill Biopharma financial statements provide useful quarterly and yearly information to potential Redhill Biopharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Redhill Biopharma financial statements helps investors assess Redhill Biopharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Redhill Biopharma's valuation are summarized below:
Gross Profit
45.3 M
Profit Margin
3.6625
Market Capitalization
13.3 M
Enterprise Value Revenue
1.4028
Revenue
6.5 M
There are over one hundred nineteen available trending fundamental ratios for Redhill Biopharma, which can be analyzed over time and compared to other ratios. We recommend to check out Redhill Biopharma's recent fundamental drivers against the all of the trends between 2010 and 2024. The value of Market Cap is estimated to slide to about 9 M. The Enterprise Value is projected to slide to about 4.1 M

Redhill Biopharma Total Revenue

6.19 Million

Check Redhill Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Redhill main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 348.6 K or Selling General Administrative of 18.4 M, as well as many exotic indicators such as Price To Sales Ratio of 1.38, Dividend Yield of 0.0 or PTB Ratio of 4.17. Redhill financial statements analysis is a perfect complement when working with Redhill Biopharma Valuation or Volatility modules.
  
This module can also supplement various Redhill Biopharma Technical models . Check out the analysis of Redhill Biopharma Correlation against competitors.
For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.

Redhill Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets21.9 M23 M66.3 M
Slightly volatile
Other Current Liabilities12.9 M15.2 M11.8 M
Slightly volatile
Total Current Liabilities33.1 M19.2 M30.3 M
Slightly volatile
Other Liabilities2.8 M5.3 M2.8 M
Slightly volatile
Accounts Payable4.2 M3.3 M3.8 M
Slightly volatile
CashM6.4 M19.9 M
Very volatile
Long Term Debt101 M96.2 M42.4 M
Slightly volatile
Common Stock Shares Outstanding6.8 M6.5 M1.3 M
Slightly volatile
Other Current Assets757.2 K797 KM
Very volatile
Total Liabilities19.9 M21 M44.2 M
Slightly volatile
Preferred Stock Total Equity1.6 K1.8 KK
Slightly volatile
Intangible Assets5.3 M5.6 M18.9 M
Slightly volatile
Common Stock22.5 M21.4 M3.5 M
Slightly volatile
Property Plant Equipment5.1 M4.9 M1.9 M
Slightly volatile
Property Plant And Equipment NetM1.2 M1.7 M
Slightly volatile
Non Current Assets Total6.6 M6.9 M22.8 M
Slightly volatile
Other Assets19.5 M18.6 M5.8 M
Slightly volatile
Cash And Short Term InvestmentsM6.4 M30.8 M
Very volatile
Net Receivables3.1 M3.3 M7.3 M
Slightly volatile
Common Stock Total Equity1.3 M1.2 M638.4 K
Slightly volatile
Liabilities And Stockholders Equity21.9 M23 M66.9 M
Slightly volatile
Non Current Liabilities Total1.6 M1.7 M14.5 M
Slightly volatile
Other Stockholder Equity217 M388.4 M187.7 M
Slightly volatile
Property Plant And Equipment Gross2.2 M2.4 M1.9 M
Slightly volatile
Total Current Assets15.3 M16.1 M44.1 M
Slightly volatile
Long Term Investments137 K174.8 K125.5 K
Slightly volatile
Net Invested CapitalM2.1 M48.7 M
Very volatile
Capital Stock22.5 M21.4 M3.8 M
Slightly volatile
Short and Long Term Debt Total1.1 M1.2 M22.5 M
Slightly volatile
Current Deferred Revenue0.860.98.9 M
Pretty Stable
Capital Lease Obligations1.1 M1.2 M3.8 M
Very volatile
Short Term Debt682.1 K718 K8.6 M
Slightly volatile
Short and Long Term Debt92.2 M103.7 M112.9 M
Slightly volatile

Redhill Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense348.6 K367 KM
Slightly volatile
Selling General Administrative18.4 M28.9 M16.9 M
Slightly volatile
Other Operating Expenses54.2 M37.9 M49.6 M
Slightly volatile
Research Development3.3 M3.5 M14.1 M
Pretty Stable
Total Operating Expenses43.9 M34.4 M40.2 M
Slightly volatile
Total Revenue6.2 M6.5 M16.7 M
Slightly volatile
Cost Of Revenue3.3 M3.5 M14.8 M
Pretty Stable
Interest Income176.2 K94 K242 K
Slightly volatile
Selling And Marketing ExpensesM2.1 M13.4 M
Very volatile
Reconciled Depreciation1.9 MM2.7 M
Slightly volatile

Redhill Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.2 M1.6 M2.9 M
Slightly volatile
Begin Period Cash Flow23.8 M36 M21.8 M
Slightly volatile
Capital Expenditures10.4 K11 KM
Pretty Stable
Total Cash From Financing Activities34.8 M21.4 M31.8 M
Slightly volatile
End Period Cash FlowM6.4 M19.9 M
Very volatile
Depreciation3.3 MM2.8 M
Slightly volatile
Sale Purchase Of Stock34.8 M41.8 M27.6 M
Slightly volatile
Issuance Of Capital Stock13.3 M14 M37.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.381.45214.2 K
Pretty Stable
Days Sales Outstanding175184K
Pretty Stable
Average PayablesM3.4 M3.7 M
Slightly volatile
Stock Based Compensation To Revenue0.240.252962.1195
Slightly volatile
EV To Sales0.620.65593.5 K
Pretty Stable
Payables Turnover1.01.05252.5075
Pretty Stable
Sales General And Administrative To Revenue4.214.434148.3443
Slightly volatile
Average Inventory6.7 M7.5 M8.2 M
Slightly volatile
Research And Ddevelopement To Revenue0.510.5403471
Pretty Stable
Cash Per Share0.930.981693.5503
Slightly volatile
Capex To Operating Cash Flow3.0E-43.0E-40.1397
Pretty Stable
Days Payables Outstanding354347398
Slightly volatile
Intangibles To Total Assets0.150.2420.1771
Slightly volatile
Current Ratio0.80.838810.2151
Slightly volatile
Receivables Turnover2.061.98272.4431
Pretty Stable
Graham Number4.895.1508367
Slightly volatile
Average Receivables15.5 M17.4 M18.9 M
Slightly volatile
Revenue Per Share0.961.005416.7908
Slightly volatile
Interest Debt Per Share0.230.237721.8791
Slightly volatile
Debt To Assets0.04840.05090.1569
Slightly volatile
Days Of Payables Outstanding354347398
Slightly volatile
Total Debt To Capitalization0.620.36180.3334
Slightly volatile
Quick Ratio0.480.50129.9243
Slightly volatile
Dividend Paid And Capex Coverage Ratio3.4 K3.3 K574
Slightly volatile
Net Income Per E B T1.141.00261.0414
Very volatile
Cash Ratio0.310.33056.7434
Slightly volatile
Days Of Sales Outstanding175184K
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.261.00031.157
Very volatile
Fixed Asset Turnover10.175.510311.7007
Pretty Stable
Capital Expenditure Coverage Ratio3.4 K3.3 K574
Slightly volatile
Debt Ratio0.04840.05090.1569
Slightly volatile
Price Sales Ratio1.381.45214.2 K
Pretty Stable
Asset Turnover0.30.28260.1559
Slightly volatile

Redhill Biopharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapM9.5 M103.6 M
Slightly volatile
Enterprise Value4.1 M4.3 M103.9 M
Pretty Stable

Redhill Fundamental Market Drivers

Forward Price Earnings1428.5714
Cash And Short Term Investments6.4 M

Redhill Upcoming Events

26th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Redhill Biopharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Redhill Biopharma income statement, its balance sheet, and the statement of cash flows. Redhill Biopharma investors use historical funamental indicators, such as Redhill Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Redhill Biopharma investors may use each financial statement separately, they are all related. The changes in Redhill Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Redhill Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Redhill Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Redhill Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue 0.90  0.86 
Total Revenue6.5 M6.2 M
Cost Of Revenue3.5 M3.3 M
Stock Based Compensation To Revenue 0.25  0.24 
Sales General And Administrative To Revenue 4.43  4.21 
Research And Ddevelopement To Revenue 0.54  0.51 
Capex To Revenue(0)(0)
Revenue Per Share 1.01  0.96 
Ebit Per Revenue(4.81)(5.05)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Redhill Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Redhill Biopharma's short interest history, or implied volatility extrapolated from Redhill Biopharma options trading.

Currently Active Assets on Macroaxis

When determining whether Redhill Biopharma is a strong investment it is important to analyze Redhill Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Redhill Biopharma's future performance. For an informed investment choice regarding Redhill Stock, refer to the following important reports:
Check out the analysis of Redhill Biopharma Correlation against competitors.
For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.
Note that the Redhill Biopharma information on this page should be used as a complementary analysis to other Redhill Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Redhill Stock analysis

When running Redhill Biopharma's price analysis, check to measure Redhill Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Redhill Biopharma is operating at the current time. Most of Redhill Biopharma's value examination focuses on studying past and present price action to predict the probability of Redhill Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Redhill Biopharma's price. Additionally, you may evaluate how the addition of Redhill Biopharma to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Is Redhill Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
4
Revenue Per Share
1.008
Quarterly Revenue Growth
(0.96)
Return On Assets
(0.16)
Return On Equity
(8.84)
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.